Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer’s Disease by Aline Dorey et al.
November 2015 | Volume 6 | Article 2471
Original research
published: 27 November 2015
doi: 10.3389/fneur.2015.00247
Frontiers in Neurology | www.frontiersin.org
Edited by: 
Raymond Scott Turner, 
Georgetown University, USA
Reviewed by: 
Benedict C. Albensi, 
University of Manitoba, Canada 
Zhihui Yang, 
University of Florida, USA
*Correspondence:




Biochemistry and Molecular Genetics 
Department, Centre Hospitalier 
Universitaire de Limoges, Limoges, 
France
Specialty section: 
This article was submitted to 
Neurodegeneration, 







Tholance Y, Fourier A and Quadrio I 
(2015) Cerebrospinal Fluid Aβ40 
Improves the Interpretation of Aβ42 
Concentration for Diagnosing 
Alzheimer’s Disease. 
Front. Neurol. 6:247. 
doi: 10.3389/fneur.2015.00247
cerebrospinal Fluid aβ40 improves 
the interpretation of aβ42 
concentration for Diagnosing 
alzheimer’s Disease
Aline Dorey1,2 , Armand Perret-Liaudet1,2,3* , Yannick Tholance2,4† , Anthony Fourier2,3  
and Isabelle Quadrio2,3
1 Center for Memory Resources and Research, Hospices Civils de Lyon, Charpennes Hospital, Lyon 1 University, 
Villeurbanne, France, 2 Neurochemistry Unit, Biochemistry Department, Hospices Civils de Lyon, Groupement Hospitalier Est, 
Bron, France, 3 BioRaN Team, Lyon Neuroscience Research Center, CNRS UMR 5292, INSERM U1028, Lyon 1 University, 
Bron, France, 4 WAKE Team, Lyon Neuroscience Research Center, CNRS UMR5292, INSERM U1028, Lyon 1 University, 
Lyon, France
The combination of decreased amyloid β42 (Aβ42) and increased total tau proteins 
(T-Tau) and phosphorylated tau (P-Tau) in cerebrospinal fluid (CSF) has recently been 
considered as a biological diagnostic criterion of Alzheimer’s disease (AD). Previous 
studies showed significant heterogeneity in CSF Aβ42 levels to discriminate AD from 
non-AD patients. It was also suggested that the CSF amyloid peptide β42/β40 ratio has 
better diagnostic performance than Aβ42 alone. The objective of the present study was 
to investigate the potential added value of determining CSF amyloid β40 peptide (Aβ40) 
for biological diagnosis of AD when CSF Aβ42 levels failed. CSF AD biomarkers were 
run in 2,171 samples from 1,499 AD and 672 non-AD patients. The following pathologic 
thresholds were used to define an AD-positive CSF biomarker profile: T-Tau ≥ 400 ng/L, 
P-Tau181 ≥ 60 ng/L, and Aβ42 ≤ 700 ng/L. CSF Aβ40 was assayed in AD patients 
with CSF Aβ42 levels above 700 ng/L and non-AD patients with CSF Aβ42 levels below 
700 ng/L. CSF Aβ40 levels were higher in AD than non-AD patients. The receiver opera-
tor characteristic curves of CSF Aβ40 and the Aβ42/Aβ40 ratio defined AD cut-off values 
at 12,644 ng/L and 0.06, respectively. In AD patients with non-pathological CSF Aβ42, 
CSF Aβ40 concentration was able to correct 76.2% of cases when expressed as CSF 
Aβ42/Aβ40 ratio and 94.7% of cases when used alone. Using CSF Aβ42 and then CSF 
Aβ40, the percentage of misinterpreted AD patients fell to 1.0%. CSF Aβ40 concen-
tration improved interpretation of Aβ42 level for the diagnosis of AD. CSF Aβ40 alone 
showed better diagnostic performance than the amyloid peptide Aβ42/Aβ40 ratio. The 
added value of determining CSF Aβ40 in AD diagnosis now needs confirming in a cohort 
of definite AD patients and to be completed with novel amyloid cascade biomarkers.
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inTrODUcTiOn
According to the revised criteria for Alzheimer’s disease (AD), 
definite diagnosis is founded on neuropathology as gold stand-
ard, when patients meet the clinical and cognitive criteria for AD 
dementia (1). Diagnosis of AD onset during the patient’s lifetime 
is said to be “possible” or “probable.” Amyloid β42 (Aβ42), total 
Tau (T-Tau), and phosphorylated Tau proteins (P-Tau) assay in 
cerebrospinal fluid (CSF) is recommended to increase the level 
of diagnostic certainty for AD in atypical clinical phenotypes, 
for inclusion of patients in clinical trials and to improve AD 
diagnosis at the earliest stages of the disease (1–5). A positive 
AD CSF biomarker profile was defined as increased CSF Tau 
and/or P-Tau181 and decreased CSF Aβ42 concentrations (1, 
6–8). However, researchers and clinicians continue to debate the 
sensitivity and specificity of various biomarkers, and especially 
CSF Aβ42. A recent meta-analysis highlighted significant het-
erogeneity in CSF Aβ42 values between different disease groups 
(9), reporting sensitivity and specificity ranging from 71 to 91% 
and 44 to 82%, respectively. Moreover, Rosen et al. showed that 
“normal” CSF Aβ42 levels were observed in AD patients, leading 
to misinterpretation of the AD CSF biomarker profile in 23.2% of 
AD patients (10).
One of the crucial challenges to improve screening in clinical 
trials is to identify an accurate CSF biomarker reflecting amyloid 
pathology. There is now strong evidence that CSF Aβ42 levels 
depend not only on impaired brain clearance in Alzheimer’s 
pathophysiology, but also on the total load of amyloid peptides, 
which shows large interindividual variability (11–14). Gamma-
secretase cleaves amyloid precursor protein (APP) at several 
sites, resulting in different C-terminally truncated Aβ variants: 
amyloid β40 (Aβ40) is the most abundant amyloid peptide in 
CSF (15), while Aβ42 accounts for only about 10% of the total 
Aβ peptide population (12, 16–18). Total Aβ concentration 
was found not to vary significantly between various dementia 
disorders (11, 18, 19), and Aβ40 concentration did not differ 
between AD (or presymptomatic AD) patients, healthy controls, 
and non-AD dementia patients (19–23). CSF Aβ40 concentration 
could, therefore, be considered to most closely reflect total Aβ 
load in the brain (13). Previous studies showed that the Aβ42/
Aβ40 ratio in CSF is reduced in AD patients, and its assessment 
improves AD diagnostic accuracy (21–25). More recently, a few 
studies demonstrated added value for CSF Aβ40 or CSF Aβ42/
Aβ40 ratio for differential diagnosis of AD using CSF P-Tau181 
levels or in ambiguous AD CSF biomarker profiles (26–28). 
Therefore, the objective of the present study was to investigate 
whether determining CSF Aβ40 level and CSF Aβ42/Aβ40 ratio 
could improve diagnosis in AD patients without low CSF Aβ42 
levels.
MaTerials anD MeThODs
Cerebrospinal fluid samples were collected between October 
2010 and January 2013 from 2,171 patients who underwent 
lumbar puncture (LP) for routine clinical diagnosis of AD in 
the Neurochemistry Unit and Biochemistry Department of the 
University Hospital of Lyon (France). Patients were included in 
a multicenter memory clinic and had at least 2 years’ follow-up. 
They were classified into two groups: 1,499 AD and 672 non-AD 
patients. The non-AD group consisted of 259 patients with prob-
able frontotemporal lobar degeneration (FTLD), 119 with prob-
able dementia with Lewy bodies (DLB), 159 with normal pressure 
hydrocephalus (NPH), and 135 with psychiatric disorders.
The patients’ age, gender, and mini mental state evaluation 
(MMSE) score were recorded when the LP was performed. At 
that time, initial diagnosis was based on medical history, caregiver 
interviews, neurologic examination, neuropsychological battery 
evaluation, and brain imaging. Clinical diagnosis was made in 
multidisciplinary team meeting, comprising neurologists, neu-
ropsychologists, and radiologists, and confirmed on follow-up. 
Dementia was defined according to DSM IV-TR criteria (29), 
and all AD patients were classified as having AD dementia with 
evidence of the AD pathophysiological process (1). Patients with 
mild cognitive impairment were excluded. The non-AD patients 
diagnosed with FTLD and DLB met the international criteria 
(30, 31). The non-AD patients with psychiatric disorders or NPH 
with cognitive complaints unrelated to AD or other degenera-
tive disease were age matched with AD patients, and showed no 
progression of cognitive impairment within 2  years after CSF 
analysis.
This study, based on routine biological analyses, was not 
considered as “biomedical research” under French regulations, 
and therefore did not require informed consent. Samples were, 
however, stored in a biobank with authorization from the 
French Ministry of Health (Declaration number DC-2008-304). 
Authorization for handling personal data was granted by the 
French data protection commission [Commission Nationale de 
l’Informatique et des Libertés (CNIL)].
All patients underwent LP to collect CSF using a standard 
procedure. CSF collection, sampling, and storage were per-
formed according to the international consensus (32, 33). All 
CSF samples were collected in Sarstedt polypropylene tubes (ref. 
62.610.201) showing low adsorption of amyloid peptides (7). CSF 
biomarker analyses were performed, blind to clinical diagnosis, 
in the Neurochemistry Unit and Biochemistry Department of 
the University Hospital of Lyon. This department is involved 
in two external quality control schemes, one at French national 
level (working group of the French Society of Clinical Biology: 
Société Française de Biologie Clinique) and the other with the 
Alzheimer’s Association QC program (34). CSF concentrations 
of Aβ42, T-Tau, and P-Tau181 were measured using the standard-
ized commercially available sandwich ELISA kit (INNOTEST®) 
according to the manufacturer’s procedures (Fujirebio, Ghent, 
Belgium).
For each CSF sample, Aβ42, T-Tau, and P-Tau181 biomarkers 
were simultaneously analyzed. As previously described (7), the 
cut-off values defining positive AD CSF biomarker profile were: 
T-Tau ≥ 400 ng/L, P-Tau181 ≥ 60 ng/L, and Aβ42 ≤ 700 ng/L.
Aβ40 level in CSF was quantified using ELISA tests [Human 
Amyloid b (1–40) (N) Assay kit, IBL, Japan] in AD patients with 
CSF Aβ42 levels above 700 ng/L and in non-AD patients with CSF 
Aβ42 levels below 700 ng/L.
TaBle 1 | Demographic, pathologic, and biological parameters of study 
populations.
aD non-aD
Gender n 1,499 672
M/F 643/856 358/314
Age (years) n 1,499 672
Mean 71.6 70.0
SD 9.5 10.6
MMSE score (/30) n 1,093 488
Mean 20.2 21.6
SD 5.6 5.5
T-Tau (ng/L) n 1,499 672
Median 650 230
25th–75th P 487–913 168–311
P-Tau181 (ng/L) n 1,499 672
Median 83 38
25th–75th P 68–109 30–48
Aβ42 (ng/L) n 1,499 672
Median 539 807
25th–75th P 443–663 570–1,056
Aβ40 (ng/L) n 281 244
Median 19,198 7,112
25th–75th P 15,162–22,409 5,643–9,636
Aβ42/Aβ40 ratio n 281 244
Median 0.053 0.066
25th–75th P 0.041–0.059 0.049–0.084
AD, Alzheimer’s disease; MMSE, mini mental state evaluation; M, male; F, female; SD, 
standard deviation; P, percentile.
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statistical analysis
Chi-square test, Mann–Whitney U test, Kruskal–Wallis test, and 
receiver operator characteristic (ROC) analyses were performed 
using MedCalc version 11.3.1.0 (http://www.medcalc.be). 
Differences were considered statistically significant at p < 0.05. 
ROC curves were applied to define optimal biomarker cut-off 
values to discriminate between AD and non-AD groups. The cut-
off value was defined as the value corresponding to the highest 
average for sensitivity and specificity. Accuracy was calculated as 
the sum of true positives and true negatives in the total number 
of patients (35).
resUlTs
Cerebrospinal fluid data according to diagnostic group are sum-
marized in Table 1 and Figure 1.
About 81.3% of AD patients (1,218/1,499) fulfilled the 
pathological CSF Aβ42 criteria; the remaining 18.7% (281/1,499) 
presented CSF Aβ42 levels above cut-off (>700 ng/L). 63.7% of 
non-AD patients (428/672) presented CSF Aβ42 levels above 
700 ng/L; 36.3% (244/672) had CSF Aβ42 levels below 700 ng/L 
(Figure 2). CSF Aβ40 levels were then determined in these 525 
patients: 281 AD patients (>700 ng/L) and 244 non-AD patients 
(≤700 ng/L).
The ROC curves of CSF Aβ40 level and the Aβ42/Aβ40 ratio 
determined AD cut-off values of ≥12,644 ng/L and ≤0.06, respec-
tively (Figure 3).
In the overall population, the percentage of patients in whom 
amyloid pathology was misinterpreted fell from 24.2% (525/2,171) 
using CSF Aβ42 alone to 7.8% (169/2,171) when it was followed 
by CSF Aβ42/Aβ40 ratio, and to 1.7% (37/2,171) when followed 
by CSF Aβ40 (Figure 2). In patients in whom CSF Aβ40 level was 
determined (n = 525), sensitivity and specificity for AD diagnosis 
were 76.2 and 58.2%, respectively (accuracy, 0.678) using the CSF 
Aβ42/Aβ40 ratio, and 94.7 and 91.0%, respectively (accuracy, 
0.930) using CSF Aβ40 determination.
About 58.2% of the 244 non-AD patients with CSF Aβ42 
levels below 700  ng/L (142/244) had CSF Aβ42/Aβ40 ratios 
higher than 0.06 and 91.0% (222/244) had CSF Aβ40 levels below 
12,644 ng/L.
About 76.2% of AD patients (214/281) had CSF Aβ42/Aβ40 
ratios below 0.06 and 94.7% (266/281) had CSF Aβ40 levels 
higher than 12,644 ng/L. In the overall AD population, percent-
age misinterpretation fell from 18.7% (281/1,499) with CSF Aβ42 
alone to 4.5% (67/1,499) using CSF Aβ42 and then CSF Aβ42/
Aβ40 ratio and 1.0% (15/1,499) using CSF Aβ42 and then CSF 
Aβ40 (Figure 2).
DiscUssiOn
We investigated the potential added value of CSF Aβ40 assay to 
improve the interpretation of Aβ42 level. The main finding was 
that CSF Aβ40 appeared to be an interesting complementary 
biomarker. CSF Aβ40 levels were higher in AD than non-AD 
patients. Thus, determining CSF Aβ40 concentrations corrected 
biological diagnosis in AD patients with non-pathological CSF 
Aβ42 levels in 76.2% of cases using the CSF Aβ42/Aβ40 ratio and 
in 94.7% using CSF Aβ40 alone; using CSF Aβ42 and then CSF 
Aβ40, percentage misinterpretation fell to 1.0%.
Cerebrospinal fluid Aβ42 concentrations led to misinterpreta-
tion of the AD CSF biomarker profile in 24.2% of our total popu-
lation and notably in 18.7% of AD patients. This low performance 
of CSF Aβ42 is in perfect agreement with previous reports (7, 
10, 18, 20, 36, 37). The presence of CSF Aβ42 concentrations 
≤700 ng/L in non-AD patients could reflect low total CSF amy-
loid load, while CSF Aβ42 >700 ng/L in AD patients could result 
from high amyloid load. This concept justifies CSF Aβ40 assay to 
complete amyloid pathway interpretation.
As reported in various studies (20, 26, 27, 36), the CSF Aβ42/
Aβ40 ratio showed better diagnostic performance than CSF Aβ42 
alone. The CSF Aβ42/Aβ40 ratio cut-off value at 0.06 was identi-
cal to that reported by Lewczuk et al. (36). The discrepancy with 
Hansson et al.’s (20) 0.095 cut-off might be due to the Genetics 
Company ELISA kit halving the range of CSF Aβ40 levels. We 
found an increase in the rate of correct interpretation from 
75.8% with CSF Aβ42 alone to 92.2% when CSF Aβ42 assay was 
followed by determining the CSF Aβ42/Aβ40 ratio, similarly to 
other reports (20, 28, 36).
The type of sampling and storage tubes is an important 
source of variability because of amyloid adsorption (33, 37, 38). 
CSF sample selection from biological banks should, therefore, 
be performed rigorously. There is parallel adsorption of CSF 
Aβ42 and Aβ40 onto the sampling tube surface, regardless of 
the type of plastic (personal data). Systematic use of the CSF 
Aß42/Aß40 ≤ 0.06 diagnoses 214 AD pa nts
 (23.8% of misinterpreted AD pa nts or 4.5% of total AD pa nts)
Aß40 ≥ 12,644 ng/L diagnoses 266 AD pa nts
(5.3% of misinterpreted AD pa nts or 1.0% of total AD pa nts)
AD, n= 1,499
non-AD, n= 672
Aß42/Aß40 misinterpreted popul on
n= 169
32.2% of Total misinterpreted subpopul on
7.8% of Total popula n
Aß40 misinterpreted popula n
n= 37
7.0% of Total misinterpreted subpopul on
1.7% of Total popula n
Remaining misinterpreted AD, n= 67, 23.8% of AD pa nts with Aß42 > 700 ng/L Remaining misinterpreted AD, n= 15, 5.3% of AD pa nts with Aß42 > 700 ng/L
Remaining misinterpreted non-AD, n= 102, 41.8% of non-AD pa nts with Aß42 ≤ 700 ng/L Remaining misinterpreted non-AD, n= 22, 9.0% of non-AD pa nts with Aß42 ≤ 700 ng/L
non-AD, n= 244, 36.3% of non-AD pa nts
Aß40 assays
Added value of CSF Aß42/Aß40 ra Added value of CSF Aß40




Total CSF Aß42 misinterpreted subpopul on
n= 525
24.2% of Total popula n
AD, n= 281, 18.7% of AD pa nts
FigUre 2 | Patient classification based on the determination of cerebrospinal fluid (csF) amyloid peptides. First, according to CSF Aβ42 levels, we 
obtained a percentage of misinterpreted patients with discordant results regarding clinical diagnosis. The CSF Aβ40 assay was performed in this subpopulation. 
Performance in accurately classifying patients was tested for CSF Aβ42/Aβ40 ratio and for CSF Aβ40 alone. Both CSF Aβ42/Aβ40 ratio and CSF Aβ40 could 
reclassify a high percentage of patients. CSF Aβ40 provided the best correct classification rate. Abbreviation: AD: Alzheimer’s disease.
FigUre 1 | csF aβ42/aβ40 ratio (a) and csF aβ40 concentrations in nanograms per liter (B) in aD and non-aD populations. Abbreviation: AD: 
Alzheimer’s disease.
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Aβ42/Aβ40 ratio would provide complete interpretation of CSF 
amyloid biomarker results, integrating the impact of plastic 
tube type. In the present study, however, samples were analyzed 
sequentially, leading to higher between-run imprecision for 
the CSF Aβ42/Aβ40 ratio than for CSF Aβ42 alone [coefficient 
of variation (CV), 13.3 and 10.2%, respectively]. One solution 
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to decrease the CV of the CSF Aβ42/Aβ40 ratio would be to 
use multiplex assays to analyze both amyloid peptides simul-
taneously. Unfortunately, at the moment, there is no analytical 
validation available for CSF Aβ42 and CSF Aβ40 in multiplex 
assays for in vitro diagnostic use.
In the present study, CSF Aβ40 was determined only in AD 
patients with CSF Aβ42 levels above 700  ng/L and in non-AD 
patients with levels below 700  ng/L. CSF Aβ40 concentrations 
were significantly higher in AD than non-AD patients. The 
optimal CSF Aβ40 cut-off value was 12,644 ng/L. To our knowl-
edge, there is currently no effective CSF Aβ40 cut-off value to 
discriminate AD from non-AD patients reported in the literature; 
only a slight increase in CSF Aβ40 was found in two other stud-
ies (20, 24), and a recent study focusing on AD-MCI patients 
found a significant increase in CSF Aβ40 values compared to a 
control group (36). However, the present data contrasted with 
those reported in another study (26) including AD and non-AD 
dementia. Selection of the non-AD patient population to compare 
with the AD population was probably one of the major differ-
ences. Another difference may be the biological factor used for 
the patients’ initial classification, CSF P-Tau181 concentrations in 
intermediate levels (26). Similarly, Sauvee et al. suggested using 
the CSF Aβ42/Aβ40 ratio when data for CSF Aβ42 combined to 
CSF P-Tau181 are inconclusive (27). In these particular cases, 
adding the CSF Aβ42/Aβ40 ratio improved their proportion of 
interpretable biological profiles from 68 to 89% (27). Moreover, 
in confirmation of our sequential approach, Sauvee et al. showed 
that adding CSF Aβ40 peptide concentration and CSF Aβ42/
Aβ40 ratio did not change their conclusions when CSF Aβ42 and 
CSF P-Tau181 were concordant.
In the present study, it was also interesting that 36.3% of 
non-AD patients presented pathological CSF Aβ42 levels. One 
hypothesis could concern the heterogeneity of the non-AD popu-
lation, which included patients with psychiatric disorders and 
NPH and demented patients with neurodegenerative diseases 
(FTLD and DLB). CSF Aβ42 was previously reported to be less 
effective for differential diagnosis of the main neurodegenerative 
dementia than CSF Tau proteins (39–41). To discriminate AD 
and FTLD, CSF Aβ42 assay could then be combined with Tau 
proteins and expressed as T-Tau/Aβ42 and P-Tau181/Aβ42 
ratios (42, 43). Typical CSF AD profiles including CSF Aβ42 and 
Tau proteins were reported in 47% of patients meeting clinical 
diagnostic criteria for DLB and in 30% of FTLD patients (41), 
suggesting coexisting pathologies, as strongly highlighted by 
postmortem studies (44, 45). NPH patients also have lower CSF 
amyloid peptide and Tau protein concentrations than controls 
(46, 47). To validate our hypothesis and strategy regarding dif-
ferential diagnosis, postmortem confirmation on autopsy-proven 
patients should be carried out.
The diagnostic performance of CSF Aβ42 is increasingly ques-
tioned. It should be noted that biological diagnosis as performed 
in specialized memory clinics is also founded on the second 
pathway of AD pathophysiology, reflected by CSF Tau protein 
levels. Nevertheless, a more accurate evaluation of CSF amyloid 
biomarkers is important to include patients in therapeutic trials 
involving the amyloid cascade, using added Aβ peptides or other 
amyloid cascade biomarkers. For example, the soluble peptide 
APPβ (sAPPβ) and CSF Aβ40 come from the same enzymatic 
digestion of APP, and it would be interesting to assess sAPPβ to 
complete this study. Increased CSF sAPPβ levels were already 
reported in AD patients as compared to non-AD demented 
patients (48) and FTD patients (49).
In conclusion, the present study offers an improvement in 
biological diagnosis of AD focusing on the amyloid pathway. 
In the misinterpretation using CSF Aβ42 levels, classification 
based on the CSF Aβ42/Aβ40 ratio gives good results. More 
interestingly, CSF Aβ40 assay alone also provides better results: 
the misinterpretation rate using CSF Aβ42 and then CSF Aβ40 
alone falls to 1.7%. Sequential assessment of CSF Aβ40 would 
also provide a better cost-effectiveness ratio than systematic 
determination of the CSF Aβ42/Aβ40 ratio. Finally, these results 
need to be confirmed in a prospective study including autopsy-
proven AD patients, and completed with novel amyloid cascade 
biomarkers.
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FigUre 3 | receiver operating characteristic curve comparison for 
aD diagnosis in the “discordant csF aβ42 values” subpopulation. 
DeLong et al.’s (1988) method was used to compare the values of the area 
under the curve (AUC). In the 525 selected patients, accuracy of diagnostic 
performance was significantly higher for CSF Aβ40 compared to CSF Aβ42/
Aβ40 ratio, with 94.7% sensitivity and 91.0% specificity for CSF Aβ40 
≥12,644 ng/L (AUC, 0.969) compared to 76.2 and 58.2%, respectively for 
CSF Aβ42/Aβ40 ratio ≤0.06 (AUC, 0.700).
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